89Zr-labeled versus 124I-labeled αHER2 fab with optimized plasma half-life for high-contrast tumor imaging in vivo

Journal of Nuclear Medicine

Volumn 56, Issue 7, 2015, Pages 1112-1118

  Mendler, Claudia T ^a,b   Gehring, Torben ^a   Wester, Hans Jürgen ^a   Schwaiger, Markus ^b   Skerra, Arne ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Fab; HER2; PASylation; PET; Plasma half life

Indexed keywords

ALANINE; DEFEROXAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN F(AB) FRAGMENT; IODINE 124; IODOTYROSINE; MACROGOL; PROLINE; RADIOISOTOPE; SERINE; TRASTUZUMAB; UNCLASSIFIED DRUG; ZIRCONIUM; ZIRCONIUM 89; AMINO ACID; CONTRAST MEDIUM; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER PATIENT; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG STABILITY; ELECTROSPRAY MASS SPECTROMETRY; ENDOCYTOSIS; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE FUSION; GLOMERULUS FILTRATION; HUMAN; HYDRODYNAMICS; KIDNEY TUBULE ABSORPTION; MOLECULAR SIZE; MOUSE; NONHUMAN; PLASMA HALF LIFE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIOACTIVITY; RADIOIODINATION; TUMOR VOLUME; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; CHEMISTRY; DIAGNOSTIC USE; HALF LIFE TIME; ISOTOPE LABELING; NEOPLASM; SCINTISCANNING; TISSUE DISTRIBUTION;

AMINO ACIDS; ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CONTRAST MEDIA; FEMALE; HALF-LIFE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IODINE RADIOISOTOPES; ISOTOPE LABELING; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION; ZIRCONIUM;

EID: 84936749542     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.149690     Document Type: Article

References (31)

1. Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 2010;146:264-275.
2. McCabe KE, Wu AM. Positive progress in immunoPET: not just a coincidence. Cancer Biother Radiopharm. 2010;25:253-261.
3. Lear-Kaul KC, Yoon HR, Kleinschmidt-DeMasters BK, McGavran L, Singh M. Her-2/neu status in breast cancer metastases to the central nervous system. Arch Pathol Lab Med. 2003;127:1451-1457.
4. Börjesson PK, Jauw YW, de Bree R, et al. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med. 2009;50:1828-1836.
5. Divgi CR, Pandit-Taskar N, Jungbluth AA, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: A phase I trial. Lancet Oncol. 2007;8:304-310.
6. Disselhorst JA, Brom M, Laverman P, et al. Image-quality assessment for several positron emitters using the NEMA NU 4-2008 standards in the Siemens Inveon small-animal PET scanner. J Nucl Med. 2010;51:610-617.
7. Meijs WE, Haisma HJ, Klok RP, et al. Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice. J Nucl Med. 1997;38:112-118.
8. Severin GW, Engle JW, Barnhart TE, Nickles RJ. 89Zr radiochemistry for positron emission tomography. Med Chem. 2011;7:389-394.
9. Perik PJ, Lub-De Hooge MN, Gietema JA, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006;24:2276-2282.
10. Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zrtrastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586-592.
11. Schlapschy M, Binder U, Börger C, et al. PASylation: A biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins. Protein Eng Des Sel. 2013;26:489-501.
12. Mendler CT, Friedrich L, Laitinen I, et al. High contrast tumor imaging with radio-labelled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation. MAbs. 2015;7:96-109.
13. Holmes WE, Sliwkowski MX, Akita RW, et al. Identification of heregulin, a specific activator of p185erbB2. Science. 1992;256:1205-1210.
14. Vosjan MJ, Perk LR, Visser GW, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc. 2010;5:739-743.
15. Perk LR, Vosjan MJ, Visser GW, et al. p-Isothiocyanatobenzyl-desferrioxamine: A new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging. 2010; 37:250-259.
16. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med. 1998;25:201-212.
17. Darrouzet E, Lindenthal S, Marcellin D, Pellequer JL, Pourcher T. The sodium/ iodide symporter: state of the art of its molecular characterization. Biochim Biophys Acta. 2014;1838:244-253.
18. Hosseinimehr SJ, Tolmachev V, Orlova A. Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design. Drug Discov Today. 2012;17:1224-1232.
19. Dijkers EC, Kosterink JG, Rademaker AP, et al. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med. 2009;50:974-981.
20. Tinianow JN, Gill HS, Ogasawara A, et al. Site-specifically 89Zr-labeled monoclonal antibodies for immunoPET. Nucl Med Biol. 2010;37:289-297.
21. Duncan JR, Behr TM, DeNardo SJ. Intracellular fate of radiometals [letter to the editor]. J Nucl Med. 1997;38:829.
22. Boswell CA, Marik J, Elowson MJ, et al. Enhanced tumor retention of a radiohalogen label for site-specific modification of antibodies. J Med Chem. 2013; 56:9418-9426.
23. Gao W, Liu W, Christensen T, Zalutsky MR, Chilkoti A. In situ growth of a PEGlike polymer from the C terminus of an intein fusion protein improves pharmacokinetics and tumor accumulation. Proc Natl Acad Sci USA. 2010;107:16432-16437.
24. Vegt E, de Jong M, Wetzels JF, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med. 2010;51:1049-1058.
25. Shih LB, Thorpe SR, Griffiths GL, et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: A comparison of nine radiolabels. J Nucl Med. 1994;35:899-908.
26. Dennis MS, Jin H, Dugger D, et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res. 2007;67:254-261.
27. Altai M, Varasteh Z, Andersson K, Eek A, Boerman O, Orlova A. In vivo and in vitro studies on renal uptake of radiolabeled Affibody molecules for imaging of HER2 expression in tumors. Cancer Biother Radiopharm. 2013;28: 187-195.
28. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol. 2004;22:701-706.
29. Kenanova V, Olafsen T, Williams LE, et al. Radioiodinated versus radiometallabeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy. Cancer Res. 2007;67:718-726.
30. Verel I, Visser GW, Boerman OC, et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm. 2003;18:655-661.
31. Knowles SM, Zettlitz KA, Tavaré R, et al. Quantitative immunoPET of prostate cancer xenografts with 89Zr-and 124I-labeled anti-PSCA A11 minibody. J Nucl Med. 2014;55:452-459.